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Abstract
Background: Previous research shows that existing asthma quality of life questionnaires fail to measure the burden
of oral corticosteroids that can be used to treat severe asthma, and are therefore not fit for purpose for severe
asthma according to the USA’s Food and Drug Administration (FDA) criteria for content validity. Patient input
and documentation of that input is key to achieving content validity according to FDA guidelines. This paper
describes the process of constructing a new questionnaire to measure the burden of asthma symptoms and
burden of treatment in severe asthma, using criteria specified by the FDA.
Methods: A draft severe asthma questionnaire (SAQ) was constructed using qualitative input from severe
asthma patients who took part in an earlier study. The aim of this study was to improve that draft questionnaire using a
further group of patients. In four iterative focus groups, 16 people with severe asthma completed the draft questionnaire,
discussed the wording and structure and suggested changes that were incorporated into the final version.
Results: The original intention to ask patients to identify whether problems were caused by asthma symptoms or side
effects of medication was abandoned as the attribution of cause was found to be difficult and inconsistent. The recall
period of 2 weeks was acceptable but fails to reflect the patients’ desire to express the variability of severe asthma.
Patients suggested improvements to the wording of the draft questionnaire, including splitting some items in two,
combining two items in one, and changes to some of the words in individual items and the response scale.
Conclusions: The final version of the questionnaire was substantially different from one constructed using only
qualitative reports from patients about the quality of life deficits of severe asthma. Patients make a valuable
contribution to the questionnaire if they are asked to comment and improve an initial draft and where patients
are treated as partners in the process of questionnaire construction, rather than only as a source of information
to experts who construct the questionnaire.
Keywords: Assessment, Content validity, Questionnaire construction, Methodology, Patient reported outcome,
Severe asthma
* Correspondence: mhyland@plymouth.ac.uk
1School of Psychology, University of Plymouth, Plymouth PL4 8AA, UK
2Plymouth Hospital’s NHS Trust, Plymouth, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hyland et al. Health and Quality of Life Outcomes _#####################_
DOI 10.1186/s12955-018-0851-9
Background
Several asthma specific quality of life scales have been
developed [1–3], and are used in clinical trials of asthma
treatments. The development of these commonly used
asthma specific scales occurred at a time before the pub-
lication of the USA’s Food and Drug Administration
(FDA) recommendations for scale validity. The FDA rec-
ommendation is based on the concept of ‘fit for purpose’
where validity is relative to the population and use [4],
and contrasts with earlier psychometric approaches [5].
Although these earlier scales may satisfy both the psy-
chometric and FDA criteria for validity for mild or mod-
erate asthma, none are fit for purpose for patients with
severe asthma because they fail to capture some of the
health-related quality of life deficits that characterise this
particular group of patients [6], namely, those resulting
from the effects of treatment burden [7].
The documentation provided by the FDA [4] proposed
that questionnaire construction should be an iterative
process involving: (a) concept definition, including a
description of the population and the use to which the
scale is put, (b) content validation where the items are
constructed and evaluated using qualitative studies and
(c) a construct and other validation using quantitative
data. This paper describes the concept definition and
content validation of a severe asthma quality of life scale
that is fit for purpose as defined by the FDA.
Concept definition
Severe asthma is defined as asthma that requires treat-
ment with high dose inhaled corticosteroids plus a sec-
ond controller and/or systemic corticosteroids to
prevent it from becoming “uncontrolled” or that remains
“uncontrolled” despite this therapy [8].
In contrast to mild or moderate asthma, two distin-
guishing features of severe asthma are (a) poor asthma
control causing symptom variability over time including
exacerbations that may require inpatient care and (b) an
increased burden of side effects from medication. The
concept of health-related quality of life in this instance
must therefore include both types of deficit. The Severe
Asthma Questionnaire (SAQ) is intended to measure is
the quality of life burden of asthma symptoms and the
side effects of asthma medication as perceived by people
who meet the criteria for severe asthma. The scale is
intended to be appropriate for use in clinical trials where
different types of asthma treatment are compared, as
well as providing a monitoring tool in clinical practice.
In order to be useful in these contexts, the SAQ should
enable patients to describe their health-related quality of
life in a way that is meaningful to the patient, to be suffi-
ciently short and easy to complete so as to reduce pa-
tient burden, and to have response scales that are
sensitive to change.
The high burden of treatment in severe asthma, espe-
cially oral corticosteroids, is important because of the
development of new biologic agents that, in addition to
improving asthma control, can lead to a reduction in the
use and hence side effects of oral corticosteroids. In an
evaluation of the quality adjusted life years (QALY) one
of these biologic agents, the National Institute for Care
Excellence (NICE) noted that “some benefits of avoiding
the adverse effects of oral corticosteroid use had not
been fully captured in the QALY measure. P. 45” [9].
Frustration has been expressed by physicians about the
process of evaluating the cost effectiveness of biologics
[10] which they feel underestimates the benefit of these
new treatments.
Although the primary intention is to have a single
questionnaire that captures both the benefits and side ef-
fects of treatment in a single metric, there would be
merit if these two aspects could be disambiguated so as
to provide information for clinical practice. Thus, there
is an extension to the concept defined above, namely to
provide independent assessments of the burden of
asthma symptoms and the burden of side effects of
asthma treatment. This extension was based on the
assumption that that patients could identify two compo-
nents of health-related quality of life: that caused by the
symptoms of the disease, and that caused by the symp-
tom side effects of treatment.
Content validity
The FDA documentation specifies that qualitative stud-
ies should ensure that the “domains of an instrument
are appropriate and comprehensive relative to its
intended measurement concept, population, and use”
[4]. We have previously documented the domains of
quality of life deficit in severe asthma, identifying two
broad domain categories, (activities and emotional im-
pact) and 11 more specific domains (hospitalisation, de-
pression, irritability, sleep, hunger, weight, skin, gastric,
pain, disease anxiety, and medication anxiety.) For each
of these domains the proportion of patients experiencing
the problem was identified. This earlier research can be
used to identify the domains of a questionnaire [6].
The FDA documentation of patient reported outcomes
(PRO) specifies that studies should provide a “test of
whether patients understand the items” and establish
that “the concepts represented in the PRO instrument’s
conceptual framework are confirmed, that the response
options and recall period are appropriately compre-
hended, and that the instrument’s readability is adequate
for the intended population.” [4]. The FDA do not spe-
cify how their objectives are achieved as different
methods may be appropriate in different circumstances,
but it is logical that studies evaluating patient under-
standing of a questionnaire should be carried out after a
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draft questionnaire has been constructed. That is, there
should be two stages in the process of qualitative
research: a first stage of domain identification which can
be used by the researchers to construct a questionnaire,
and a second stage when patients are given a question-
naire to comment on and their comments then can be
used to confirm or change the existing wording, includ-
ing the conceptual framework. Both wording and con-
ceptual framework could differ between patients and
researchers.
A 15 item draft questionnaire was constructed on the
basis of domains identified in our earlier research [6],
reflecting the frequency of problems identified by
patients in that earlier study, and with the structure of
the questionnaire modelled on the Asthma Bother Pro-
file (ABP) [11]. The ABP is the only asthma scale that
was constructed using the two stage process of qualita-
tive research (described above) for mild or moderate
people with asthma. The structure of the questionnaire,
based on patient preference, is to have key words (e.g.,
social life, personal life), written in large text, and, for
some items examples of what is meant by the key words
written afterwards (e.g., visiting friends, walking with
friends, talking with friends, going to bars/restaurants
and parties). The response options for the Asthma
Bother Profile are degrees of bother caused in each of
the specified areas of concern. For this scale, the re-
sponse options were a 7-point scale of how your life was
affected with patients asked to attribute whether the
aspect of life was attributed to asthma symptoms,
asthma medicines except oral steroids, and oral steroids.
A global health-related quality of life scale was added at
the end of the questionnaire, following the design used
by the EQ-5D-5 L where a visual analogue scale (VAS) is
added after the initial five questions [12]. Unlike the
EQ5D VAS which measures perceived health, we based
the 100 point scale on a global quality of life scale
(GQoL), which is a 100 point Borg scale of quality of life
[13]. Patients were asked to rate their quality of life on
average and to separately estimate their quality of life
due to asthma symptoms and side effects of medicine.
The aim of this study was to improve this draft ques-
tionnaire by presenting it to patients and asking for
comments and ways of improving it.
Methods
Participants
Patients who were attending a severe asthma clinic in the
UK were invited to attend a focus group. Patients were se-
lected so as to recruit both genders, a range of ages and se-
verity assessed by British Thoracic Society (BTS) steps of
asthma management (which is defined by treatment) and
representative of the population of patients seen in this
clinic. There were four focus groups, 16 participants of
whom 12 were female, with ages ranging from 24 to
69 years and a mean age of 47 (SD = 13.53). Participants
were at BTS steps 3, 4, and 5. More females than males
were able to take part in these day-time focus groups.
Procedure
Patients gave written informed consent to take part in a
study on the development of a questionnaire, and com-
pleted the questionnaire on arrival. The purpose of the
focus group was explained – for patients to help con-
struct a severe asthma questionnaire. Patients were
asked specific questions about every element of the
questionnaire, including the introductory words, the re-
sponse scale, and the individual items. For each element
the patients were asked to describe what they under-
stood by the meaning of the element and individual
words in the element. Patients were encouraged to dis-
cuss if and how the element under consideration could
be improved, including the balance between different
types of item in the questionnaire. The sessions were
moderated by one of the authors, observed by another,
and changes recommended by patients noted. The rec-
ommended changes were then implemented into the
next version of the questionnaire which was presented
to the subsequent group. All authors contributed to and
approved the final version of the questionnaire. The ses-
sions lasted up to 2 h and were audio recorded.
The study was approved by the Plymouth Hospitals
NHS Trust, ethical approval number 16/NE/0188, IRAS
ID: 207,601.
Results and discussion
Information gained from patients during the iterative
process of questionnaire modification can be divided
into four categories.
Change to the concept
One of the aims of questionnaire development was to
provide independent assessments of the impact of
asthma symptoms versus the impact of the side effects
of asthma medicines on quality of life. Despite iterative
changes in wording, we found that although some pa-
tients in each focus group could answer the question of
relative impact, significant problems arose for some pa-
tients and these are noted below.
First, some patients noted the difficulty in identifying
asthma medicines from other medicines, and in particu-
lar those medicines that were taken to counteract the
side effects of asthma medicines. Patients differed as to
whether these side effect medicines should be consid-
ered asthma medicines or not.
P5. I have a lot of medication, that counteracts
medication that I’m on, but I still consider it my
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asthma medication, because it’s all for that. So would
you include things like that? 16.20. 20/07/16
P1. Zopiclone sleeping tablets, because you get, stop
sleeping when you’re on 10mg. 16.25. 20/07/16
P2. And I know that Zopiclone that I’m now on, does
have side effects, and it’s addictive, and I’m now
addicted to it. 19.25. 20/07/16
Second, the issue of deciding between disease versus
treatment was perceived as difficult and unfamiliar task.
P15. It’s actually like making my brain think. Cos I’ve
never been asked any of these questions before, in the
whole time I’ve been under Consultants and
everything, I’ve never been asked any of this stuff.
14.11. 22/07/16
Third, for patients who had been on long term oral
corticosteroids since childhood, many were unaware that
this type of medication had side effects.
P13. It’s very difficult, as you tend to ignore those as
life, rather than these are side effects caused by your
medication. 08.05. 21/07/16 PM
P16. I think what’s interesting here is, I’m not sure
what the side effects are. 25.03. 22/07/16.
Finally, some symptoms may be caused either by
the disease or treatment. For example, patients can
experience fatigue after an exacerbation requiring ad-
mission to hospital (which of particular problem in
relation to child care), but it is unclear whether fa-
tigue is a response to the exacerbation, the reduction
in oral corticosteroids or simply the stay in hospital.
The conclusion drawn from patient feedback was that it
is possible for some patients to make a meaningful assign-
ment of problems to asthma symptoms versus side effects
of medicine. However, because in each focus group one or
more patients who reported problems in relation to this
concept, the conclusion was any assessment of the con-
cept of symptom attribution would not be content valid.
Changes to recall period
The moderator explained to patients that the aim of the
questionnaire was to use it in clinical trials, and that a 2
week recall period is used elsewhere [3]. Patients found
a 2 week but not a 4week recall period acceptable.
Yea, last couple of weeks. Four weeks is really hard.
How many people can remember how you were four
weeks ago? 40.50 20/07/17
P6. I think if you’re going into, if you want detail then
two week is about my limit really [laughs]. 09.06. 21/
07/16 AM
The use of a 2 week period was supported by a second
participant who was critical of other asthma QoL ques-
tionnaires used as part of clinical practice that require a
4 week assessment period.
P4. It’s bad enough when you go to the chest clinic
and fill them out isn’t it. Because they say, in the
last four weeks how have you been feeling, and I’m
thinking, that’s four weeks ago. 06.30. 20/07/16
However, although patients could report on the last
2 weeks, they felt that this recall period provided a
poor description of their experience of asthma.
P7. It sounds extremely like you are going on textbook
asthma, but asthma is never textbook. 31.17 21/07/17
AM
Patients would like to be able to express how their
asthma affected them over a longer time period.
P7. The thing is, if you want a genuine direct
answer, and you want the best results possible, you
probably would have to break it down into months.
07.28. 21/07/16 AM.
P3. Just do 3 sections and say, what’s it been like in the
last 12 months, and then particularly the last 6
months, and then particularly in the last month.
40.00. 20/07/16
Patients indicated that their symptoms and quality
of life varied with the season.
P13. I know exactly when I will be ill, I know that
I really struggle with the mould season in the
autumn, and that in the spring, between February
and May is my good time of year. 11.05. 21/07/16
PM
P7. Think seasons’ll be good because people are
going to be affected, as you say depending on,
what their aller [sic], you know the allergic
asthmatics. So if you’re allergic to the funguses in
the autumn, you might be worse in the autumn,
you’ve got the spring flowers, you’ve got the
summer grass. 06.40. 21/07/16 AM
Patients also indicated they would like to assess their
quality of life on average.
Hyland et al. Health and Quality of Life Outcomes _#####################_ Page 4 of 9
P3. You have a chance at remembering how you felt
on average, because you can have bad days and you
can have good days. 41.00. 20/07/16
In order to satisfy the competing demands of a
clinical trial and the patients’ desire to provide a
more holistic description of their asthma, one solu-
tion explored was to ask patients to rate all items
on a 2 week period but also, on a separate page, to
assess global health-related quality of life during the
four seasons of the year. The additional questions
about the four seasons (i.e., four global questions,
one for each season) was found acceptable by pa-
tients in the focus groups. After the focus groups
were completed, an international group of clinicians
advised that seasons do not apply in some countries.
In order to satisfy patient preference without refer-
ring to seasons, four global season questions were
replaced by one global question to assess quality of
life during the last 2 weeks and two global questions
to assess quality of life during the best and worst
months of the year. This solution was found accept-
able by a small group of patients in clinic.
Changes to the response scale
The initial response scale for the 15 items consisted
of a 7-point scale of how a patient’s life was affected,
with patients asked to write a number in a box to
show whether the aspect of life was attributed to
asthma symptoms, asthma medicines except oral ste-
roids, and oral steroids.
As reported above, patients found it difficult to at-
tribute cause to symptoms, and several felt that tick
boxes were preferable to writing numbers. Because of
patient feedback, subsequent versions of the response
scale were simplified to a tick box scale.
The meaning of the words used in the response scale
was discussed. Patients interpreted the word ‘restricted’
– the word used in the original format of the scale – in
a sense equivalent to ‘I am unable to’ rather than in
terms of a limitation that varied in degree, and patients
suggested the term ‘difficult’ instead.
P7. difficult I would find better because restricted, you
know, means there’s a limit, you know, difficult could
be to any degree. 43.20. 21/07/16 AM
Following discussion, the final questionnaire has a
response scale with a 7 point difficulty scale: very,
very difficult (worst possible); very difficult; difficult;
moderately difficult; slightly difficult; very slightly
difficult (just noticeable); no problem, with quanti-
fiers taken from earlier research on the use of quan-
tifiers in category rating scales [13]. This final
version was confirmed separately with patients in
clinic.
Changes to the wording, structure and content of the
items
Although the term exacerbation was not used in the
questionnaire, when the moderator suggested that
sometimes health professionals used words that pa-
tients did not like, patients gave the following
response.
P4. And stop calling it, ex…
P1. Oh exacerbation (Mispronounced).
P4. Nobody calls it that! We all call it asthma attack.
57.30. 20/07/16
Patients suggested several changes to the items and
wording of the questionnaire and this was done itera-
tively. In an early version of the questionnaire there
was a question about family life. Patients were asked
to rate the difficulty of their asthma and its treatment
associated with “My family life. For example: child
care, family responsibilities”. Discussion indicated that
there were two very different aspects of family life:
that of the patient and that of the patient’s family.
The impact of family is much pronounced in severe
asthma because of the frequency of exacerbations and
hospitalisation.
P6. Yea it should be recognised that peoples’ families
are taking on a burden. 42.53. 21/07/16 AM
As a result, the final version of the questionnaire has
two items relating to family life (see Table 1).
In the draft questionnaire, there was one item con-
cerning worries about medicines. Discussion with pa-
tients showed that there were two distinct concerns: that
asthma medicines would become less effective over time,
and that the medication would produce side effects.
P2. Omeprazole, if you’re on it long term, can be quite
damaging. 19.00. 20/07.17
P1. Steroids used to improve my life, I thought they
were wonderful because I was able to do things, and
now I am at the stage where I am taking a lot of
steroids every day and I can’t. I struggle with the
stairs, I struggle to have a shower, you know it’s, it’s
crap. 24.11. 20/07/17
P1. I used to think of the benefits, now I think of the
side effects because I’m reaping them. 14.40. 20/07/17
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Patients therefore felt that the item on medication
should be split in to two to reflect two very different
concerns about medication (see Table 1).
P6. Should there be somewhere about the more longer
term problems, like the cataracts and the diabetes, so
that you’ve got a record all these. 53.41. 21/07/16 AM
Although patients felt that some items should be split,
they felt that two items could be combined, namely the
items on weight and on embarrassment, as having two
items provided excessive emphasis on this aspect of
quality of life deficit.
P9. When you out “getting anxious” umm, it kinda
combines with “the way I look” also. What I’ve just
said you know, people pre-guessing exactly what is
wrong with you, because you’re not in a wheelchair.
52.11. 21/07/16 AM
Another patient reflected that they felt self-conscious
as a result of having asthma, which stemmed from the
public’s lack of understanding of the disease.
P8. There’s a stigma about asthma isn’t there. 52.35.
21/07/16 AM
In addition to changes to the structure of the ques-
tionnaire, patients also made changes to wording within
items. Patients pointed out that a question about sleep
did not ask about periods during the night when the pa-
tient was unable to sleep.
P16. What about night times? 28.20. 22/07/16
P16. Well sometimes, I have er, so I don’t disturb the
wife, I go downstairs, you know I use my pumps and
all that, but I go downstairs, so I don’t wake her up.
You know, I do get umm tight chest night times, and
I’m woken up. 28.32 22/07/16
P16. If I’m tired, you know, and I wanna go to sleep,
and you can’t go to sleep, and sometimes it does get to
you, you know. Well upset I suppose. 29.16 22/07/16.
P14. Mines worse if I’ve got a chest infection as well,
and then I’ve got my nebuliser right beside my bed.
29.32 22/07/16.
The word ‘night time’ was therefore used with sleep as
an example of what happens at night.
Other changes involved amplification. For example, in
the original scale there was an item ‘I get tired’. The final
version is “Getting tired. For example, feeling tired for
no reason, waking in the morning feeling tired.”
Patients were asked to compare the final version of the
SAQ with other questionnaires completed in clinic. Re-
sponses were positive, none negative.
P14. The one in the clinic feels like, it’s very kind of
like medical, and have you done any exercise? Have
you lost sleep? Umm, it’s kind of, they are just trying to
establish how bad your asthma is at that point before
you go and see the Consultant. Whereas these ones feel
more, how your quality of life in general is, which I’ve
never been asked about. Which is something which
really frustrates me and this is the first time I’ve been
asked about it.
14:47. 22/07/16
Conclusions
This study demonstrates that more than one type of
qualitative research is need to achieve content validity.
An initial questionnaire was written on the basis of in-
terviews with 23 patients [6]. That initial questionnaire
Table 1 Table showing the principal item changes between the first and final version of the questionnaire
Initial questionnaire item(s) presented to focus groups Final questionnaire item(s) after iterative changes
3. I am restricted in my family life. For example: child care,
family responsibilities.
6. My family life – how it affects me. For example: caring for children, family
responsibilities.
7. My family life – how it affects others. For example: others taking time off work,
problems with childcare, family members becoming upset.
10. I worry about my asthma and treatment in the future.
For example, asthma getting worse, long term side
effects of medicines.
11. Worry that asthma may get worse. For example, medicines no longer help, more
frequent attacks.
12. Long term side effects of medicines. For example, cataracts, diabetes, bone
fracture.
12. My sleep is disturbed. For example, difficulty going
to sleep, being woken very easily, waking often at night.
14. Problems at night. For example, difficulty going to sleep, being woken very
easily, waking often at night.
13. I dislike the way I look. For example, I don’t like my
weight, my skin bruises easily.
15. I get embarrassed. For example, I don’t like using my
medicines in public, I don’t like having asthma
symptoms in public.
15. The way I look. For example, my weight, my skin bruises easily, using medicines
in public, other people judging me.
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was written by a team that included a psychologist who
had constructed ten published scales of which four relate
to respiratory medicine, a physician who had con-
structed a questionnaire for COPD patients, and a re-
spiratory specialist leading a severe asthma clinic.
Despite the expertise of this group, feedback from pa-
tients who evaluated that questionnaire created a final
version that was not only radically different from the ini-
tial, but also differed in concept.
Patients who are prescribed OCS have poorer health-
related quality of life [14], and greater health resource
utilisation possibly attributable to side effects of OCS
[15]. Interest in assessing the side effects of OCS is
motivated by the development of new biologic agents
that can control inflammation in asthma and other in-
flammatory diseases and therefore reduced the burden
of OCS and its side effects. Feedback from patients
showed that whereas some could identify whether a
symptom was caused by OCS or asthma symptoms,
there were four problems that could make the attribu-
tion of cause difficult for patients. These problems are
compounded by that fact that exacerbations lead to in-
creased OCS exposure, but exacerbations are defined by
worse asthma symptoms. That patients have difficulty in
attributing cause to disease versus side effects of OCS
has been reported in other disease areas [16], and
Fig. 1 The process of questionnaire development of the SAQ
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attribution of cause in other contexts shows that people
often make incorrect attributions [17]. Because of the
number of patients having problems with the attribution
of cause (at least one in each focus group), the original
intention to provide separate measures of asthma symp-
toms and medicine side effects was abandoned.
Although the initial qualitative interviews led to a 15
item questionnaire, the outcome of the second phase of
qualitative research was to produce a 16 item question-
naire. Patients changed the structure and balance of the
items. Two of the original items were split into two cre-
ating four out of the original two items, but two of the
original items were combined. Patients made other
changes to content of the items, and they also made
changes to the response scale. Although the unsuitability
of the term ‘exacerbation’ has been noted before [18],
we found problems with additional words where pa-
tient and health professional interpretations were
slightly different.
The SAQ is designed for clinical trial use in asthma
where an assessment period of 2 weeks is appropriate
for underlying biological changes. A 2 week assessment
period is applied in a commonly used asthma specific
questionnaire [3]. Severe asthma is characterised by fre-
quent exacerbations, and patients were clear that any 2
week period of assessment does not capture the full im-
pact over the course of a year. The FDA documentation
states that the recall period should be appropriate for
“The population, disease state, or application of the
instrument” [4]. The problem we faced was that a 2
week recall period is appropriate for the intended appli-
cation of a clinical trial, but not for the patients’ own
perceptions of the disease state. We therefore adopted a
compromise where 16 items and one global scale refer
to a 2 week period, but patients are also asked to rate
their global quality of life in their worst and best
months. However, it should be noted that a deficit mea-
sured in any 2 week period therefore cannot be general-
ised over a year. The problem of generalisation is
important for health resource allocation. The EQ-5D-
5 L [12] assesses health impact during the day of assess-
ment. A very large sample would be needed to random-
ise out the variation of asthma that occurs in severe
asthma over a period of a year. In addition, the impact
of asthma can vary by seasons. Thus, point measurement
of a variable condition has the potential for error.
The recall period of 2 weeks is appropriate for a clin-
ical trial, but patients also have a narrative they want to
tell the clinician. Time estimation is influenced by inter-
est and enjoyment [19, 20]. The global questions at the
end of the questionnaire contribute to a more positive
experience of questionnaire completion which, on the
basis of reports from patients in this study, is often lack-
ing in other questionnaires. The SAQ takes between
three and 6 min to complete and produces two scores:
an aggregation of the 16 domain relevant items to pro-
duce an SAQ score for the last 2 weeks, and a SAQ-
global score produced from the single global estimate of
quality of life over the last 2 weeks. The worst and best
month scores can be used for clinical purposes but the
research use (for example, in detecting response shift)
has not been determined. The questionnaire can be
downloaded from www.saq.org.uk.
Edwards et al. [1] list problems that can reduce the
content validity of a scale. Qualitative research can help
avoid those problems. A diagrammatic summary of the
steps taken in content validation is shown in Fig. 1. In
our earlier study we showed that existing asthma specific
scales failed to include items relevant to the burden of
treatment. In the study reported here, patients commen-
ted on a draft questionnaire and these comments then
led to alterations to the concept; that some items should
be split in two whereas others should be combined, that
changes should be made to the response options and
time periods and changes to wordings of individual
items. Finally, this study has shown the considerable
benefits of treating patients as partners in the process of
questionnaire. A considerable body of research shows
how the language used by health professionals differs
from patients [18]. Engaging patients as partners can
produce, what patients perceive as an improved ques-
tionnaire, compared to treating patients only as sources
of information.
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